Yesterday evening, the World Health Organization (WHO) approved the Sinovac vaccine developed by the Chinese company Kexing Pharmaceutical to be added to the emergency use list, making it the seventh new crown vaccine to be certified by WHO for safety, effectiveness and quality.
It is reported that the WHO independent expert team said in a statement that it is recommended that Kexing's vaccine be used for adults over 18 years of age, and a second injection should be given 2-4 weeks later.
There is no upper age limit because the data shows that it has a protective effect on the elderly.
This is the second domestic vaccine that has been urgently approved by the WHO.
The previous one is the Chinese National Medicine vaccine that was added to the list on May 7.